Aster DM Healthcare merger: Rs 4,000 crore bed plan

Why Aster DM’s next phase is in focus

Aster DM Healthcare has outlined a multi-year expansion plan for India as it moves closer to merging with Quality Care India Ltd (QCIL). Founder and Chairman Dr Azad Moopen said the company has earmarked around ₹4,000 crore of capital outlay over the next few years to add about 4,080 beds. The update comes alongside shareholder approval for the proposed Scheme of Amalgamation with QCIL, a transaction that would create a larger hospital platform across multiple states. The company has said the merger is expected to be completed in the next quarter, subject to remaining regulatory and statutory approvals from the National Company Law Tribunal (NCLT). The combined entity is expected to operate under the name Aster DM Quality Care Ltd. Aster’s management has positioned India as the key growth market for the merged platform.

Shareholders clear the merger proposal

On March 13, 2026, Aster DM Healthcare said it received 96.68% voting approval from shareholders, along with a significant majority of minority shareholders and creditors, for the amalgamation with QCIL. The approval also follows support for the share swap preceding the merger, indicating broad-based backing for the overall structure of the deal. Dr Moopen said the vote reflected shareholder confidence in the strategic rationale and the long-term value expected from combining the two hospital businesses. In its communication, the company described the merged platform as a scaled, future-ready healthcare group with a stronger governance framework. While multiple reports reiterate the same vote outcome, the company has consistently highlighted that the final closing still depends on the last set of statutory steps.

Regulatory path and expected closing timeline

Aster DM has said the merger is expected to be completed in the next quarter after receiving remaining NCLT approvals. Separately, the company has also indicated the closing is pending regulatory and compliance requirements, including NCLT processes, with one update pointing to completion by Q1 FY27. Earlier in the process, the transaction had already received approvals from the Competition Commission of India (CCI) and the stock exchanges. These steps reduce key regulatory uncertainties, but the scheme cannot be implemented until the NCLT process is completed. Investors typically track such deals through milestones like tribunal orders, filing timelines, and the formal effective date of the scheme.

What the combined Aster DM Quality Care platform includes

Upon completion, the combined entity is expected to be among the top three hospital chains in India, based on the company’s statements. It is expected to have a diversified presence across 9 states and 28 cities. The merged platform is slated to operate 39 hospitals with 10,625+ beds. The platform is also expected to be supported by over 36,307+ employees and clinicians, serving millions of patients annually across hospitals, clinics, laboratories, and allied healthcare services. Separately, one report referenced a current base of 10,265 beds and a longer-term ambition to reach around 14,710 beds over the coming years.

The bed addition roadmap: 4,080 planned beds

Dr Moopen said Aster DM Healthcare plans to add 4,080 beds over the next few years supported by a capital outlay of approximately ₹4,000 crore. Of the planned additions, 2,368 beds are to be added by Aster DM, with the remaining beds to be added by QCIL. Aster DM has also been reported to plan ₹2,300 crore investment to add 2,368 beds through a mix of greenfield projects and selective acquisitions over the coming years. The company’s messaging has emphasised that India remains the key growth market for the merged entity, particularly after the separation of its GCC business.

Projects cited by the company

Aster DM has indicated specific projects in its pipeline. These include a 300-bed Women and Children’s Hospital in Hyderabad and a 75-bed expansion at Aster Ramesh, Ongole. In a separate update referenced in the provided material, Aster also announced a ₹580 crore investment for a new 500-bed hospital in Yeshwanthpur, Bengaluru. Some reports also listed additional planned capacity, including two new hospitals in Bengaluru with 430 and 500 beds respectively, a 454-bed hospital in Thiruvananthapuram, and a 100-bed capacity increase at Aster Medcity in Kochi. These project references illustrate the blend of new hospitals and brownfield expansions that can support bed growth targets.

Financial and operating snapshot disclosed in updates

Multiple financial datapoints were cited across the supplied material, including standalone and pro forma numbers. A merger note cited FY25 revenue for Aster DM Healthcare at ₹4,138 crore with EBITDA of ₹806 crore (19.5% margin), and QCIL FY25 revenue at ₹3,963 crore with EBITDA of ₹855 crore (21.5% margin). For H1 FY26, the same note cited Aster revenue at ₹2,275 crore and EBITDA at ₹478 crore (21.0% margin), while QCIL reported revenue of ₹2,271 crore and EBITDA of ₹514 crore (22.7% margin). It also cited a pro forma merged entity H1 FY26 revenue of ₹4,546 crore and operating EBITDA of ₹993 crore (21.8% margin), with a net debt to operating EBITDA ratio of 0.71x.

Another update on Q3 FY26 pro forma performance (Aster + QCIL) cited revenue of ₹2,366 crore (up 15% year-on-year) and operating EBITDA of ₹503 crore (up 22% year-on-year), with an operating EBITDA margin of 21%. QCIL’s standalone Q3 FY26 numbers were cited as revenue of ₹1,181 crore (up 17% year-on-year) and operating EBITDA of ₹279 crore (up 32% year-on-year), with a margin of 23.7%. A separate market update cited Aster’s quarterly revenue at ₹1,078 crore (up 8% year-on-year), operating EBITDA at ₹215 crore (up 21% year-on-year), and post-minority interest PAT at ₹90 crore.

Leadership and governance structure after the merger

Dr Azad Moopen will continue as Executive Chairman, while Varun Khanna (Group MD, QCIL) is set to assume the role of Managing Director and Group CEO. The governance structure described in the company’s update states that Aster promoters and Blackstone will hold equal board representation and jointly control the company, while independent directors will constitute 50% of the board. This structure is meant to reflect shared control and a formal governance framework that includes a strong independent director presence.

Key facts at a glance

What this means for investors and the hospital sector

If executed on the timelines indicated, the transaction would consolidate two sizeable hospital networks and expand Aster’s reach beyond its traditionally strong southern markets. One report cited the combined platform’s ambition to expand into states such as Madhya Pradesh, Odisha, Chhattisgarh, and Tamil Nadu. The bed addition plan, combined with greenfield developments and selective acquisitions, implies sustained capital deployment over multiple years. For listed healthcare providers, growth is often tracked through bed additions, occupancy trends, payer mix, and margins; the pro forma disclosures in the updates provide a baseline for how the combined platform has been performing.

The market’s immediate focus is likely to remain on closing mechanics, including NCLT approvals and the effective date of the scheme. Aster has also indicated it may consider strategic fundraising after completing the merger, depending on capital requirements and alignment with expansion priorities. Any such fundraising, if pursued, would be evaluated against the scale of capex plans and the company’s stated bed growth targets.

Conclusion

Aster DM Healthcare’s plan to deploy around ₹4,000 crore to add about 4,080 beds sets a clear operating agenda as it moves toward combining with QCIL. The merger has secured shareholder backing with a 96.68% approval vote and has already received CCI and stock exchange approvals. The next formal milestone is completion of remaining NCLT approvals, after which the merged Aster DM Quality Care platform can move into execution of its stated expansion pipeline. Investors will watch for the final closing timeline and further disclosures on project phasing, capex deployment, and post-merger integration milestones.